NCT03799445 - Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 25, 2019

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Human Papillomavirus Positive Oropharyngeal Squamous Cell CarcinomaOropharyngeal Basaloid CarcinomaPathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Posterior Tongue Squamous Cell CarcinomaSoft Palate Squamous Cell CarcinomaStage III Oropharyngeal Squamous Cell Carcinoma AJCC v7Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7Tonsillar Squamous Cell Carcinoma

Interventions

RADIATION

Intensity-Modulated Radiation Therapy

Undergo IMRT

BIOLOGICAL

Ipilimumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER